Genmab A (GMAB) Work In Process (2023 - 2025)

Genmab A (GMAB) has reported Work In Process for 3 consecutive years, with $1.1 billion the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Work In Process rose 83.5% year-over-year to $1.1 billion; the trailing twelve-month figure through Dec 2025 stood at $1.1 billion (up 83.5% YoY), and the FY2025 full-year result was $1.1 billion, up 83.5% from the prior year.
• Work In Process improved to $1.1 billion in Q4 2025 per GMAB's latest filing, from $618.0 million in the prior quarter.
• Across five years, Work In Process topped out at $1.1 billion in Q4 2025 and bottomed at $190.0 million in Q4 2023.
• Historically, Work In Process has averaged $647.3 million across 3 years, with a median of $618.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Work In Process surged 225.17% in 2024, then soared 83.5% in 2025.
• Over 3 years, Work In Process stood at $190.0 million in 2023, then soared by 225.17% to $618.0 million in 2024, then jumped by 83.5% to $1.1 billion in 2025.
• According to Business Quant data, Work In Process over the past three periods registered $1.1 billion, $618.0 million, and $190.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.